SCHEMBL6538474

SCHEMBL6538474

CC(C)n1nc(-c2cc(C(N)=O)c(N)nc2-c2ccccc2)ccc1=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RET P07949 3/20 0.41
RCE1 Q9Y256 1/20 0.39
PIK3CD O00329 2/20 0.38
ABL1 P00519 2/20 0.38
EGFR P00533 2/20 0.38
HCK P08631 2/20 0.38
SRC P12931 2/20 0.38
KDR P35968 2/20 0.38
PIK3CA P42336 2/20 0.38
PIK3CB P42338 2/20 0.38
MTOR P42345 2/20 0.38
EPHB4 P54760 2/20 0.38
PRKDC P78527 2/20 0.38
PI4KB Q9UBF8 2/20 0.38
TP53 P04637 1/20 0.38
POLB P06746 2/20 0.38
IKBKB O14920 1/20 0.37
KDM4E B2RXH2 1/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6539194 0.91 RET (0.37) RETPIK3CDABL1EGFRHCK
SCHEMBL6538335 0.88 CASP1 (0.42) RETPIK3CDABL1EGFRHCK
SCHEMBL6538477 0.85 ADORA2A (0.38) RETPIK3CDABL1EGFRHCK
SCHEMBL6538926 0.84 POLB (0.39) RETPIK3CDABL1EGFRHCK
SCHEMBL6539119 0.84 ADORA2A (0.36) RETPIK3CDABL1EGFRHCK
SCHEMBL6539038 0.84 ADORA2A (0.36) RETPIK3CDABL1EGFRHCK
SCHEMBL6539045 0.83 ALDH1A1 (0.44) TP53POLBKDM4EKMT2AMAPT
SCHEMBL6539012 0.82 POLB (0.42) TP53POLBKDM4EKMT2AMAPT
SCHEMBL6538517 0.81 AKT1 (0.39) PIK3CDABL1EGFRHCKSRC
SCHEMBL5149097 0.81 RET (0.41) RETTP53POLBADORA2AMAP2K3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040067955-A1 Pyridazinone compound and pharmaceutical use thereof FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2004-04-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040067955-A1 Pyridazinone compound and pharmaceutical use thereof ADORA1, ADORA2A, P2RX5 RET 4137/4885RCE1 3777/4885PIK3CD 809/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.